SCHEMBL6016764

SCHEMBL6016764

COC(=O)Cc1ccc(OCC2CO2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.52
ALDH1A1 P00352 4/20 0.51
TP53 P04637 4/20 0.51
TSHR P16473 3/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPT P10636 2/20 0.51
HPGD P15428 2/20 0.51
HIF1A Q16665 2/20 0.51
CYP1A2 P05177 1/20 0.51
PPARG P37231 1/20 0.51
LMNA P02545 1/20 0.51
GAA P10253 1/20 0.51
MGLL Q99685 2/20 0.51
TDP1 Q9NUW8 1/20 0.50
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
CYP4F2 P78329 1/20 0.47
CYP4A11 Q02928 1/20 0.47
LIPE Q05469 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9628772 1.00 PKM (0.52) PKMALDH1A1TP53TSHRMEN1
SCHEMBL27130998 0.87 MGLL (0.68) PKMALDH1A1TP53TSHRMEN1
SCHEMBL8437625 0.86 PKM (0.50) PKMALDH1A1TP53TSHRMEN1
SCHEMBL13654852 0.86 PKM (0.50) PKMALDH1A1TP53TSHRMEN1
SCHEMBL8537967 0.86 MGLL (0.56) PKMALDH1A1TP53TSHRMEN1
SCHEMBL1041018 0.86 PKM (0.50) PKMALDH1A1TP53TSHRMEN1
SCHEMBL32684702 0.85 MGLL (0.58) PKMALDH1A1TP53TSHRMEN1
SCHEMBL9816004 0.85 ALDH1A1 (0.54) PKMALDH1A1TP53TSHRMEN1
SCHEMBL13433635 0.84 ALDH1A1 (0.46) PKMALDH1A1TP53TSHRMEN1
SCHEMBL32685136 0.83 MGLL (0.53) PKMALDH1A1TP53TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1007101-B1 IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS GE HEALTHCARE AS (NO) 2006-05-17 EP disclosed
EP-0973552-B1 IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS AMERSHAM HEALTH AS (NO) 2006-03-01 EP disclosed
US-20050002865-A1 Diagnostic/therapeutic agents AMERSHAM HEALTH AS (NO) 2005-01-06 US disclosed
US-20040141922-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2004-07-22 US disclosed
US-6680047-B2 FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS AMERSHAM HEALTH AS (NO) 2004-01-20 US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
WO-1998018501-A2 IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS MARSDEN, JOHN, CHRISTOPHER (GB) 1998-05-07 WO disclosed
EP-0256586-B1 PROCESS FOR THE PREPARATION OF ESTERS OF 4-(2,3-EPOXYPROPOXY)PHENYLACETIC ACID AND 4-(2-HYDROXY-3-ISOPROPYLAMINO-PROPOXY)PHENYLACETIC ACID AND/OR ATENOLOL IN STEREOSPECIFIC FORM GIST-BROCADES N.V. (NL) 1992-05-13 EP disclosed
US-4593119-A ADRENERGIC BLOCKING AGENTS OF SHORT DURARION AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1986-06-03 US disclosed
US-4387103-A SHORT ACTING BETA BLOCKING AGENTS AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1983-06-07 US disclosed
EP-0065542-A4 COMPOUNDS SUITABLE FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS. AMERICAN HOSPITAL SUPPLY CORP (US) 1983-04-25 EP disclosed
EP-0005610-B1 1-(HETEROCYCLYLALKYL)-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONES, THEIR PREPARATION, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS BETA-ADRENERGIC RECEPTOR BLOCKERS JANSSEN PHARMACEUTICA N.V. (BE) 1982-12-15 EP disclosed
EP-0065542-A1 COMPOUNDS SUITABLE FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS. AMERICAN HOSPITAL SUPPLY CORP (US) 1982-12-01 EP disclosed
WO-1982001869-A1 METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS AMERICAN HOSPITAL SUPPLY CORP (US) 1982-06-10 WO disclosed
EP-0053435-A1 Compounds suitable for treatment or prophylaxis of cardiac disorders AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1982-06-09 EP disclosed
US-4181802-A ADRENERGIC BLOCKING AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1980-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040141922-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 PKM 4447/4885ALDH1A1 4549/4885TP53 10/4885
US-20050002865-A1 Diagnostic/therapeutic agents FUS, HNRNPF, HNRNPR PKM 3305/4885ALDH1A1 3855/4885TP53 4/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 PKM 4441/4885ALDH1A1 4459/4885TP53 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.